JP2015525211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525211A5 JP2015525211A5 JP2015514525A JP2015514525A JP2015525211A5 JP 2015525211 A5 JP2015525211 A5 JP 2015525211A5 JP 2015514525 A JP2015514525 A JP 2015514525A JP 2015514525 A JP2015514525 A JP 2015514525A JP 2015525211 A5 JP2015525211 A5 JP 2015525211A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- cdr1
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims 42
- 108060003951 Immunoglobulin Proteins 0.000 claims 27
- 102000018358 immunoglobulin Human genes 0.000 claims 27
- 101710189965 P2X purinoceptor 7 Proteins 0.000 claims 17
- 102100037602 P2X purinoceptor 7 Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 11
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 claims 6
- 230000000890 antigenic effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000002773 nucleotide Chemical group 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654417P | 2012-06-01 | 2012-06-01 | |
| US61/654,417 | 2012-06-01 | ||
| PCT/EP2013/061257 WO2013178783A1 (en) | 2012-06-01 | 2013-05-31 | P2x7 receptor antagonists and agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018108470A Division JP6681433B2 (ja) | 2012-06-01 | 2018-06-06 | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015525211A JP2015525211A (ja) | 2015-09-03 |
| JP2015525211A5 true JP2015525211A5 (enExample) | 2016-07-21 |
| JP6608698B2 JP6608698B2 (ja) | 2019-11-27 |
Family
ID=48579032
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514525A Active JP6608698B2 (ja) | 2012-06-01 | 2013-05-31 | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト |
| JP2018108470A Active JP6681433B2 (ja) | 2012-06-01 | 2018-06-06 | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018108470A Active JP6681433B2 (ja) | 2012-06-01 | 2018-06-06 | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9908935B2 (enExample) |
| EP (1) | EP2855518A1 (enExample) |
| JP (2) | JP6608698B2 (enExample) |
| CN (1) | CN104507964B (enExample) |
| AU (2) | AU2013269606B2 (enExample) |
| WO (1) | WO2013178783A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2370465T3 (da) * | 2008-12-19 | 2019-05-06 | Ablynx Nv | Genetisk immunisering til fremstilling af immunoglobuliner mod celleassocierede antigener, såsom p2x7, cxcr7 eller cxcr4 |
| CN104507964B (zh) | 2012-06-01 | 2020-05-15 | 埃博灵克斯股份有限公司 | P2x7受体拮抗剂和激动剂 |
| WO2014182601A1 (en) * | 2013-05-08 | 2014-11-13 | Children's Medical Center Corporation | A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis) |
| HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| WO2016154683A1 (en) * | 2015-04-02 | 2016-10-06 | Biosceptre (Uk) Limited | Pain treatment |
| US10875918B2 (en) | 2015-11-12 | 2020-12-29 | Ablynx N.V. | P2X7 receptor binders and polypeptides comprising the same |
| PL233352B1 (pl) * | 2016-09-15 | 2019-10-31 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe białko fuzyjne |
| CN109321589A (zh) * | 2018-10-15 | 2019-02-12 | 潍坊医学院 | 一种制备p2x7r免疫原的方法 |
| CN110054691B (zh) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | 一种抗人p2rx7单克隆抗体的杂交瘤细胞系 |
| WO2021041194A1 (en) * | 2019-08-23 | 2021-03-04 | Unm Rainforest Innovations | Non-opioid compositions and therapies for pain management |
| AU2021389409A1 (en) | 2020-11-30 | 2023-06-22 | Asahi Kasei Pharma Corporation | Medicine for alleviating neuropathic pain |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| EP4665755A1 (en) | 2023-02-17 | 2025-12-24 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1615991A4 (en) * | 2003-04-03 | 2007-12-19 | Bristol Myers Squibb Co | POLYNUCLEOTIDE ENCODING A NEW HUMAN P2X7 SPLICE VARIANT CALLED HBMYP2X7V |
| US8124730B1 (en) * | 2004-04-02 | 2012-02-28 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v |
| DK2370465T3 (da) * | 2008-12-19 | 2019-05-06 | Ablynx Nv | Genetisk immunisering til fremstilling af immunoglobuliner mod celleassocierede antigener, såsom p2x7, cxcr7 eller cxcr4 |
| CN104507964B (zh) | 2012-06-01 | 2020-05-15 | 埃博灵克斯股份有限公司 | P2x7受体拮抗剂和激动剂 |
-
2013
- 2013-05-31 CN CN201380040371.6A patent/CN104507964B/zh active Active
- 2013-05-31 AU AU2013269606A patent/AU2013269606B2/en active Active
- 2013-05-31 US US14/403,754 patent/US9908935B2/en active Active
- 2013-05-31 WO PCT/EP2013/061257 patent/WO2013178783A1/en not_active Ceased
- 2013-05-31 EP EP13727838.8A patent/EP2855518A1/en active Pending
- 2013-05-31 JP JP2015514525A patent/JP6608698B2/ja active Active
-
2018
- 2018-01-19 US US15/874,938 patent/US10544216B2/en active Active
- 2018-06-06 JP JP2018108470A patent/JP6681433B2/ja active Active
- 2018-08-14 AU AU2018217239A patent/AU2018217239B2/en active Active